Recovery of Ovarian Function and Pregnancy in a Patient With AML After Myeloablative Busulphan-based Conditioning Regimen
Recovery of Ovarian Function and Pregnancy in a Patient With AML After Myeloablative Busulphan-based Conditioning Regimen
复制标题
DOI：
10.1097/mph.0b013e3181faf7b5
复制
发表时间：
2011-05
期刊：
影响因子：
--
通讯作者：
D. Balashov;L. Papusha;T. A. Nazarenko;P. Trakhtman;N. A. Revishvili;A. Maschan;M. Persiantseva;Anna V Andriutsa;E. Skorobogatova;Y. Skvortsova;A. Rumiantsev
中科院分区：
文献类型：
--
作者：
D. Balashov;L. Papusha;T. A. Nazarenko;P. Trakhtman;N. A. Revishvili;A. Maschan;M. Persiantseva;Anna V Andriutsa;E. Skorobogatova;Y. Skvortsova;A. Rumiantsev
我们报告了一个罕见的病例，在接受造血干细胞移植（HSCT）和基于白消安的预处理方案的第三次完全缓解的急性髓细胞白血病（AML）患者中，激素替代疗法（HRT）后卵巢功能恢复并怀孕。供体细胞成功植入并实现了完全供体嵌合，没有白血病迹象。 HSCT 一年后，患者接受了一个疗程的激素替代疗法（HRT）作为高促性腺激素性性腺功能减退症的治疗。 HRT 12 个月后，证实卵巢功能已恢复。 HSCT 自然妊娠后八年；第 7 周记录胎儿心跳。三周后出现非严重阴道出血，超声检查显示未发育妊娠。流产材料的基因检查显示出完整的三倍体基因型（69 XXX）。据我们所知，这是第一例 AML 患者在接受多个疗程的高剂量化疗和以白消安为基础的清髓性造血干细胞移植后卵巢功能恢复并自然妊娠的病例。
We report a rare case of ovarian function recovery and pregnancy after hormone-replacement therapy (HRT) in the acute myeloblastic leukemia (AML) patient in third complete remission received hematopoietic stem cell transplantation (HSCT) with busulphan-based conditioning regimen. Successful engraftment of the donor cells and full donor's chimerism was achieved without the signs of leukemia. One year after HSCT the patient received a course of HRT as a treatment of hypergonadotropic hypogonadism. After 12 months of HRT the recovery of ovarian function was confirmed. Eight years after the HSCT spontaneous pregnancy occurred; heartbeat of the fetus was registered on week 7. Three weeks later a nonsevere vaginal bleeding occurred and the ultrasound examination showed a nondeveloping pregnancy. Genetic examination of the abortion material showed a full triploid genotype (69 XXX). To our knowledge this is a first case of ovarian function restoration and spontaneous pregnancy in a AML patient after multiple courses of high-dose chemotherapy and busulphan-based myeloablative conditioning for HSCT.